What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a

What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a "single switch" between the originator and biosimilar, including the NOR-SWITCH study?

What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a “single switch” between the originator and biosimilar, including the NOR-SWITCH study; and what are the implications for clinical practice?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas